📋 HealthTech sits at the intersection of the world's largest industry ($8.3 trillion globally) and its most complex regulatory environment. Evaluating HealthTech investments requires understanding clinical workflows, regulatory pathways, reimbursement models, and evidence generation—dimensions that don't exist in other sectors. This guide provides a comprehensive framework for assessing HealthTech investment opportunities.
Before diving into evaluation frameworks, it's critical to distinguish between three related but distinct categories:
HealthTech (Digital Health): Software-first solutions for healthcare delivery, operations, and patient engagement. Examples: Veracyte (diagnostics AI), Hims & Hers (telehealth), Olive AI (RPA for health systems). Evaluated primarily as software companies with healthcare-specific risk factors.
BioTech: Drug development and biological therapeutics. Binary clinical trial risk, 10-15 year development cycles, regulatory approval gates. Requires completely different evaluation frameworks focused on clinical data, mechanism of action, and trial design. Not covered in this guide.
MedTech: Physical medical devices, from surgical robots to diagnostic equipment. Evaluated as hardware companies with FDA regulatory requirements. Partially covered here where digital components are significant.
This guide focuses on HealthTech (digital health) and the digital components of MedTech—the categories most relevant to venture investors seeking technology-driven returns in healthcare.
Our HealthTech framework evaluates six dimensions, with special emphasis on regulatory and reimbursement considerations that are unique to healthcare.
In healthcare, building a great product is necessary but insufficient. If nobody pays for it, it doesn't matter. Understanding the payment model is arguably the most important element of HealthTech evaluation.
Who pays? The HealthTech payment landscape includes: employers (self-insured, increasingly the largest buyer), health plans/payers (UnitedHealth, Anthem, Aetna), health systems/providers (hospitals, clinics), government (Medicare, Medicaid, VA), and patients (out-of-pocket, growing but limited). Each buyer has different purchasing processes, budget cycles, and value requirements.
Value-based vs. fee-for-service: The US healthcare system is transitioning from fee-for-service (paying per procedure) to value-based care (paying for outcomes). HealthTech companies aligned with value-based models—those that demonstrably reduce costs or improve outcomes—have structural tailwinds. Those dependent on fee-for-service economics face headwinds as the transition accelerates.
CPT codes and reimbursement: For clinical HealthTech products, having a CPT (Current Procedural Terminology) code and established reimbursement rate dramatically accelerates adoption. Products without reimbursement codes require innovative payment models (employer direct contracts, cash-pay) that limit market size. Evaluate whether the company has a reimbursement strategy and the timeline to achieve it.
Healthcare buyers—especially payers and health systems—require evidence that a product works. The level of evidence required depends on the claim being made and the buyer segment.
Evidence hierarchy for HealthTech: (1) Randomized controlled trials (RCTs)—gold standard but expensive and slow, (2) Peer-reviewed observational studies—good for demonstrating real-world effectiveness, (3) Case studies and pilot data—sufficient for early sales but insufficient for scale, (4) Anecdotal evidence—not useful for serious buyers.
Evidence generation strategy: The best HealthTech companies build evidence generation into their go-to-market strategy. Early customers become research partners, pilot programs generate publishable data, and positive outcomes create a virtuous cycle of evidence and adoption. Evaluate whether the company has a deliberate evidence strategy with specific milestones and publication targets.
Clinical validation red flags: Claims of efficacy without supporting data, no clinical advisory board, no IRB-approved studies, and unwillingness to submit to peer review. These suggest the company either doesn't have evidence or doesn't want to subject its claims to scrutiny.
The healthcare IT ecosystem is notoriously complex. Products must integrate with EHR systems (Epic, Cerner/Oracle Health, Athenahealth), practice management systems, billing systems, and clinical workflows. The degree of integration difficulty is one of the most common underestimated risks in HealthTech.
EHR integration: Epic and Oracle Health (formerly Cerner) control ~60% of the US hospital EHR market. Products that require deep EHR integration face long sales cycles and implementation timelines. Products that work independently of the EHR (standalone workflows, patient-facing tools) can move faster but may face adoption friction from providers accustomed to working within their EHR.
Workflow disruption assessment: Healthcare workers are creatures of habit operating under extreme time pressure. Products requiring significant workflow changes face enormous adoption barriers. The most successful HealthTech products either fit seamlessly into existing workflows or automate tasks entirely (removing workflow steps rather than changing them).
Beyond standard startup red flags, HealthTech investments have unique warning signs:
1. HIPAA hand-waving: Any HealthTech company that treats HIPAA compliance as an afterthought or uses vague language about 'being HIPAA compliant' is either naive or negligent. Evaluate: BAA agreements with hosting providers, encryption at rest and in transit, access audit logs, breach notification procedures, and regular security assessments.
2. Clinician-free teams: HealthTech companies without clinical advisors or team members with healthcare operations experience consistently underestimate workflow complexity, regulatory requirements, and buyer expectations. At least one team member or advisor should have deep clinical or healthcare operations experience.
3. 'Uber for healthcare' analogies: Be skeptical of companies that oversimplify healthcare by analogy to other industries. Healthcare's complexity is not a feature waiting to be disrupted—it's a reflection of genuine medical, regulatory, and ethical complexity. Companies that don't respect this complexity tend to build products that don't work in real clinical environments.
4. No path to enterprise scale: Many HealthTech companies sell successfully to individual practices or small clinics but can't break into health systems (where the real volume and revenue are). Evaluate the enterprise readiness: security certifications (SOC 2, HITRUST), dedicated implementation teams, and references from >500-bed health systems.
đź”— Explore More: Continue your research with our LTV/CAC Ratio Guide, Net Revenue Retention Analysis, and VC Trends 2026.
.svg.svg)